HER2-LOW BREAST CANCER

This study will follow 800 Chinese adults with advanced HER2-positive or HER2-low breast cancer who are taking trastuzumab deruxtecan (T-DXd). Researchers will track how long the drug keeps the cancer from getting worse and note any side effects. The goal is to see how well the t…

This study tests a new drug, BL-M07D1, against standard chemotherapy in 566 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. The goal is to see if BL-M07D1 can slow cancer growth better than chemo. Participants must be 18-75 years old and have t…

This study looks at how well a drug called trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer. Researchers will follow 300 patients who are already getting or will get this drug as part of their normal care. The goal is to see r…

This study tests a combination of two drugs (disitamab vedotin and bevacizumab) in people with HER2-low breast cancer that has spread and worsened after prior treatment with T-DXd. The goal is to see if the combination can shrink tumors or slow the disease. About 37 adults will t…

This study tests whether giving two different antibody drug conjugates (Dato-DXd and T-DXd) one after the other can shrink tumors in people with HER2-negative metastatic breast cancer whose cancer has already progressed after prior antibody drug conjugate therapy. About 357 parti…

This study is testing a new type of PET scan that looks for a protein called HER2 on breast cancer cells. The goal is to see if this scan can better predict which patients with advanced breast cancer will benefit from a targeted drug called T-DXd. About 70 women with metastatic b…

This study looks at specific gene changes (HRD/HRR) in people with HER2-low breast cancer, a type that doesn't have high levels of the HER2 protein. Researchers will collect tumor and blood samples from 255 participants to see how common these gene changes are and whether they af…